PharmaResearch Co., Ltd. (KOSDAQ:214450)

South Korea · Delayed Price · Currency is KRW

306,000

-8,500 (-2.70%)

Oct 2, 2026, 3:30 PM KST

Market Cap	3.18T -46.0%
Revenue (ttm)	603.58B +34.2%
Net Income	185.69B +46.2%
EPS	16,711.23 +39.2%
Shares Out	10.39M
PE Ratio	18.31
Forward PE	18.52
Dividend	3,700.00 (1.21%)
Ex-Dividend Date	Dec 29, 2025

Volume	125,045
Open	321,000
Previous Close	314,500
Day's Range	304,000 - 325,500
52-Week Range	255,000 - 606,000
Beta	0.48
Analysts	Strong Buy
Price Target	522,642.86 (+70.8%)
Est. Earnings	Nov 11, 2026

About PharmaResearch

PharmaResearch Co., Ltd., together with its subsidiaries, operates as a biopharmaceutical company primarily in South Korea. The company offers Re-An eye drops for protecting eyes from corneal damages with various causes; JBP PLAMON injection, a brown ampoule containing a pale yellow transparent liquid; ZADAXIN injection, an adjunctive therapy for influenza vaccination in immunocompromised elderly patients; PLACENTEX injection for the treatment and tissue restoration of wounds; CLEVIEL VOLUME to temporarily improve facial wrinkles in adults thro... [Read more]

Industry Medical - Pharmaceuticals

Sector Healthcare

Founded 1993

Employees 550

Stock Exchange KOSDAQ

Ticker Symbol 214450

Full Company Profile

Financial Performance

In 2025, PharmaResearch's revenue was 536.29 billion, an increase of 53.18% compared to the previous year's 350.12 billion. Earnings were 165.12 billion, an increase of 79.39%.

Financial Statements

Analyst Summary

According to 14 analysts, the average rating for 214450 stock is "Strong Buy." The 12-month stock price target is ₩522,643, which is an increase of 70.80% from the latest price.

Price Target

₩522,643

(70.80% upside)

Analyst Consensus: Strong Buy

Stock Forecasts